What does Rosetta Genomics Ltd. do?

Rosetta Genomics Ltd. (ROSGQ) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is ROSGQ's market cap?

Rosetta Genomics Ltd. (ROSGQ) has a market capitalization of approximately $593, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does ROSGQ pay a dividend?

No — Rosetta Genomics Ltd. (ROSGQ) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Rosetta Genomics Ltd. (ROSGQ) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

ROSGQ

Rosetta Genomics Ltd.

OTC·Medical, Diagnostics & Research · Healthcare

$0.00$0.00+0.00%

Market cap$593.00·Market closed·Aug 26 8:00 PM UTC

Price Chart

$0.00+$0.00 (+0.00%)today

−99.98%CAGR −81.15%

Select date range

FromTo

Feb 27, 2007Aug 27, 2021 → Aug 27, 2026· 5.0 yrsAug 27, 2026

Key Metrics

ROSGQ does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateDec 18

Last Report DateMar 30

Reported vs Estimate−$2.73 vs −$1.38

Earnings Surprise−97.8%

FinancialsFinancials Tab

Revenue$5.49M

Net Income−$14.27M

Net Margin−259.7%

Operating Cash Flow−$11.96M

Capital Expenditures$0.00

Free Cash Flow−$12.26M

Return on Equity−1,298.2%

Return on Invested Capital−38.1%

Net Debt$1.16M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for ROSGQ and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how ROSGQ's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ROSGQ and 80,000+ other tickers.

About Rosetta Genomics Ltd.

Rosetta Genomics Ltd. is a global entity specializing in genomic diagnostics. The company leverages its proprietary microRNA technologies to offer a range of diagnostic assays, including RosettaGX Cancer Origin, which helps pinpoint the primary source of metastatic cancer; mi-KIDNEY, designed for classifying kidney tumors from pathological specimens; RosettaGX Reveal, used to interpret indeterminate thyroid fine-needle aspirate results; and various mi-LUNG diagnostic tests. In addition to its microRNA-based portfolio, Rosetta Genomics provides UroVysion, a urine-based Fluorescence In Situ…

CEO: Douglas Sites
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: OTC
Employees: 86
Website: www.rosettagenomics.com

Peers

Peers Tab

ONCSQ

OncoSec Medical Incorporated

Motus GI Holdings, Inc.

Cap

$639.0

Latest News

News Tab

No recent news available.

Frequently Asked Questions About ROSGQ

What does Rosetta Genomics Ltd. do?: Rosetta Genomics Ltd. (ROSGQ) operates in the Medical - Diagnostics & Research industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is ROSGQ's market cap?: Rosetta Genomics Ltd. (ROSGQ) has a market capitalization of approximately $593, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does ROSGQ pay a dividend?: No — Rosetta Genomics Ltd. (ROSGQ) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is ROSGQ profitable?: Rosetta Genomics Ltd. (ROSGQ) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.